Last reviewed · How we verify
Crisaborole Vehicle
Crisaborole is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in atopic dermatitis.
Crisaborole, marketed by Pfizer, is a topical medication with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it in the market. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Crisaborole Vehicle |
|---|---|
| Sponsor | Pfizer |
| Drug class | Phosphodiesterase 4 (PDE4) inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Crisaborole inhibits phosphodiesterase 4, an enzyme that regulates immune cell function and inflammatory responses. By blocking PDE4, it increases intracellular cAMP levels, which suppresses the production of pro-inflammatory cytokines and reduces skin inflammation characteristic of atopic dermatitis. This mechanism allows for topical anti-inflammatory activity without systemic corticosteroid effects.
Approved indications
- Atopic dermatitis (mild to moderate)
Common side effects
- Application site burning
- Application site pain
- Skin irritation
Key clinical trials
- Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis (PHASE4)
- Steroid-reducing Effects of Crisaborole (PHASE4)
- Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo (PHASE2)
- A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis (PHASE3)
- Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis (PHASE3)
- Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis (PHASE2)
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD (PHASE4)
- Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Crisaborole Vehicle CI brief — competitive landscape report
- Crisaborole Vehicle updates RSS · CI watch RSS
- Pfizer portfolio CI